Merrimack (MACK) Buy Rating Reiterated at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Merrimack Pharma (MACK) Rips Higher on Baxter (BAX) Agreement
September 24, 2014 8:12 AM EDTMerrimack Pharmaceuticals (Nasdaq: MACK) shares are ripping in early trading following news that the company entered an exclusive agreement with Baxter International Inc. (NYSE: BAX).
According to an... More
Merrimack Pharma (MACK), Baxter (BAX) Enter Exclusive Agreement Covering MM-398
September 24, 2014 7:01 AM EDTBaxter International Inc. (NYSE: BAX) and Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) jointly announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.'' Through the agreement, Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the United States and Taiwan, and Merrimack retains commercialization rights in the United States; the rights in Taiwan are held separately.
MM-398 is an investigational drug candidate for which Merrimack is preparing a New Drug Application in the United... More
